So far there is no evidence that person-to-person transmission is occurring in the MERS outbreak to a great extent. Close contact between people seems to be required. "All three infections, Ebola, SARS, and now MERS", Fukuda says, "deeply underscore the fact that we don't have our infection prevention and control practices at anywhere near the right level and it also underscores the difficulty of getting them to the right level."
In the view of Laurie Garrett, senior fellow for global health at the Council on Foreign Relations, New York, NY, USA, getting preventive measures "to the right level" would, as a fi rst step, require WHO's International Health Regulations Emergency Committee to declare MERS a "Public Health Emergency of International Concern", as it did for the Ebola epidemic. Speaking to The Lancet, she comments: "Since the first MERS case appeared in July, 2013, the committee has met nine times and has refused to make that declaration. One reason given was the possible impact on Saudi Arabia's economy. Another was fear of panicking pilgrims to the Hajj. A third, given at the committee's latest meeting in June, was insuffi cient knowledge about the transmission of the virus. These reasons don't take into account the reality that Saudi Arabia is still being plagued by major nosocomial outbreaks amounting so far to more than 1000 cases and more than 400 deaths. If that committee doesn't act soon, we're going to be living with this virus for a very long time."
There certainly is, as the committee pointed out, a lack of knowledge about the virus. "We know that dromedary camels are reservoirs of the MERS coronavirus but we don't know if there are other animals harbouring the virus", says Fukuda. "We don't know how the virus is transmitted and we still don't understand the full spectrum of illness and pathology of the virus." To accelerate progress in resolving these unknowns, WHO has convened scientists and public health officials from the affected countries to four meetings in Cairo, Egypt, and plans to hold another in the next 6 months.
Meanwhile, research is underway. Drugs already on the market, such as ribavirin and interferon alpha 2a, are being "repurposed" for potential treatment of MERS and are seemingly being used already for patients in Saudi Arabia. A phase 2 clinical trial of serum containing antibodies from MERS survivors is planned in Jeddah, Saudi Arabia. Particularly promising results have been obtained by US researchers studying MERS treatment with antibodies from cattle engineered to carry human immunoglobulin genes. As for vaccines, about a dozen are in the pipelines of at least six drug companies and as many research groups in at least six countries, but no candidate has yet gone past the in-vitro stage. Work is also planned to develop a vaccine that would protect camels from the coronavirus.
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